Study reports impact of spaceflight on cardiovascular progenitor cell development and signaling

A new study of the effects of spaceflight on the development of heart cells identified changes in calcium signaling that could be used to develop stem cell-based therapies for cardiac repair. The impact of simulated microgravity and environmental factors on the International Space Station on cardiovascular progenitor cell development and signaling is reported in an upcoming special issue of Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website until May 2, 2018.

The article "Spaceflight Activates Protein Kinase C Alpha Signaling and Modifies the Developmental Stage of Human Neonatal Cardiovascular Progenitor Cells" is coauthored by Johnathan Baio, Aida Martinez, Leonard Bailey, Nahidh Hasaniya, Michael Pecaut, and Mary Kearns-Jonker from Loma Linda University, CA. The researchers modeled the molecular changes seen at microgravity under normal gravity conditions and discussed the implications of these adaptive cellular responses for enhancing the potential of cardiovascular progenitor cells in regenerative medicine.

"This paper provides an important proof of concept for combining space- and ground-based experimental design and informs cardiac therapeutic development both for spaceflight and here on Earth," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis